UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy

Circulation (New York, N.Y.), 2018-05, Vol.137 (21), p.2256-2273

2018

Volltextzugriff (PDF)

Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib's Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach

Combinatorial chemistry & high throughput screening, 2022-01, Vol.25 (1), p.149-166

2022

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

The New England journal of medicine, 2020-01, Vol.382 (1), p.41-50

2020

Volltextzugriff (PDF)

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib

JAMA oncology, 2018-11, Vol.4 (11), p.1527

2018

Volltextzugriff (PDF)

Pyrotinib in HER2 -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Journal of clinical oncology, 2020-08, Vol.38 (24), p.2753-2761

2020

Volltextzugriff (PDF)

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723

2020

Volltextzugriff (PDF)

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Clinical cancer research, 2018-12, Vol.24 (24), p.6195-6203

2018

Volltextzugriff (PDF)

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Cancer discovery, 2014-09, Vol.4 (9), p.1046-1061

2014

Volltextzugriff (PDF)

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2702-2709

2018

Volltextzugriff (PDF)

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Journal of clinical oncology, 2020-02, Vol.38 (5), p.488-495

2020

Volltextzugriff (PDF)

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Nature communications, 2016-06, Vol.7 (1), p.11815-15, Article 11815

2016

Volltextzugriff (PDF)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

British journal of cancer, 2019-10, Vol.121 (9), p.725-737

2019

Volltextzugriff (PDF)

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3105-3112

2017

Volltextzugriff (PDF)

Pyrotinib: First Global Approval

Drugs (New York, N.Y.), 2018-11, Vol.78 (16), p.1751-1755

Blair, Hannah A.

2018

Volltextzugriff (PDF)

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Journal of clinical oncology, 2020-02, Vol.38 (6), p.538-547

2020

Volltextzugriff (PDF)

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.933-939

2019

Volltextzugriff (PDF)

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i20-i27

2018

Volltextzugriff (PDF)

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Journal of thoracic oncology, 2019-01, Vol.14 (1), p.99-106

2019

Volltextzugriff (PDF)

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

The lancet oncology, 2015-09, Vol.16 (9), p.e447-e459

2015

Volltextzugriff (PDF)

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2019-11, Vol.25 (22), p.6644-6652

2019

Volltextzugriff (PDF)

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Lung cancer (Amsterdam, Netherlands), 2015-12, Vol.90 (3), p.509-515

2015

Volltextzugriff (PDF)

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

European journal of pharmaceutical sciences, 2017-12, Vol.110, p.51-61

2017

Volltextzugriff (PDF)

An imaging-guided platform for synergistic photodynamic/photothermal/chemo-therapy with pH/temperature-responsive drug release

Biomaterials, 2015-09, Vol.63, p.115-127

2015

Volltextzugriff (PDF)

1 – 25 von 1.050

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(992)
Mit Volltextzugriff
(899)

Publikationsform

Artikel
(1.048)
Buchkapitel
(1)
Bücher
(1)

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(935)
Humans
(885)
Life Sciences & Biomedicine
(875)
Lung Neoplasms - Drug Therapy
(617)
Acrylamides - Therapeutic Use
(510)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(510)
Oncology
(498)
Erbb Receptors - Genetics
(485)
Mutation
(482)
Lung Neoplasms - Genetics
(459)
Female
(424)
Protein Kinase Inhibitors - Therapeutic Use
(413)
Male
(407)
Carcinoma, Non-Small-Cell Lung - Genetics
(383)
Aniline Compounds - Therapeutic Use
(373)
Acrylamides
(332)
Antineoplastic Agents - Therapeutic Use
(315)
Animals
(306)
Middle Aged
(301)
Osimertinib
(287)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy

Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib's Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib

Pyrotinib in HER2 -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Pyrotinib: First Global Approval

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

An imaging-guided platform for synergistic photodynamic/photothermal/chemo-therapy with pH/temperature-responsive drug release

Suchergebnisse filtern